281 related articles for article (PubMed ID: 14755311)
1. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience.
Yusuf U; Frangoul HA; Gooley TA; Woolfrey AE; Carpenter PA; Andrews RG; Deeg HJ; Appelbaum FR; Anasetti C; Storb R; Sanders JE
Bone Marrow Transplant; 2004 Apr; 33(8):805-14. PubMed ID: 14755311
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS).
Hasle H; Aricò M; Basso G; Biondi A; Cantù Rajnoldi A; Creutzig U; Fenu S; Fonatsch C; Haas OA; Harbott J; Kardos G; Kerndrup G; Mann G; Niemeyer CM; Ptoszkova H; Ritter J; Slater R; Starý J; Stollmann-Gibbels B; Testi AM; van Wering ER; Zimmermann M
Leukemia; 1999 Mar; 13(3):376-85. PubMed ID: 10086728
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group.
Woods WG; Barnard DR; Alonzo TA; Buckley JD; Kobrinsky N; Arthur DC; Sanders J; Neudorf S; Gold S; Lange BJ
J Clin Oncol; 2002 Jan; 20(2):434-40. PubMed ID: 11786571
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina.
Basquiera AL; Pizzi S; Correas AG; Longo PG; Goldman WC; Prates MV; Formisano S; Kusminisky G; Feldman L; Berretta AR; García JJ; Staciuk R
Pediatr Blood Cancer; 2015 Jan; 62(1):153-7. PubMed ID: 25264233
[TBL] [Abstract][Full Text] [Related]
5. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
Locatelli F; Pession A; Bonetti F; Maserati E; Prete L; Pedrazzoli P; Zecca M; Prete A; Paolucci P; Cazzola M
Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia.
Witherspoon RP; Deeg HJ
Haematologica; 1999 Dec; 84(12):1085-7. PubMed ID: 10586209
[TBL] [Abstract][Full Text] [Related]
8. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group.
Arnold R; de Witte T; van Biezen A; Hermans J; Jacobsen N; Runde V; Gratwohl A; Apperley JF
Bone Marrow Transplant; 1998 Jun; 21(12):1213-6. PubMed ID: 9674854
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Runde V; de Witte T; Arnold R; Gratwohl A; Hermans J; van Biezen A; Niederwieser D; Labopin M; Walter-Noel MP; Bacigalupo A; Jacobsen N; Ljungman P; Carreras E; Kolb HJ; Aul C; Apperley J
Bone Marrow Transplant; 1998 Feb; 21(3):255-61. PubMed ID: 9489648
[TBL] [Abstract][Full Text] [Related]
10. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
Demuynck H; Verhoef GE; Zachee P; Emonds MP; van der Schueren E; van den Berghe H; Vandenberghe P; Casteels-Van Daele M; Boogaerts MA
Bone Marrow Transplant; 1996 May; 17(5):745-51. PubMed ID: 8733692
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
12. Donor lymphocyte infusion to treat relapse after allogeneic bone marrow transplantation for myelodysplastic syndrome.
Depil S; Deconinck E; Milpied N; Sutton L; Witz F; Jouet JP; Damaj G; Yakoub-Agha I;
Bone Marrow Transplant; 2004 Mar; 33(5):531-4. PubMed ID: 14716345
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Oliveira AF; Tansini A; Vidal DO; Lopes LF; Metze K; Lorand-Metze I
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27748021
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.
Anderson JE; Appelbaum FR; Schoch G; Gooley T; Anasetti C; Bensinger WI; Bryant E; Buckner CD; Chauncey T; Clift RA
J Clin Oncol; 1996 Jan; 14(1):220-6. PubMed ID: 8558201
[TBL] [Abstract][Full Text] [Related]
15. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
16. [The clinical analysis of allogeneic hematopoietic stem cell transplantation from human leukocyte antigen-identical siblings in 95 patients with myelodysplastic syndrome].
Zhao T; Huang X; Liu D; Wang J; Zhang X; Wang Y; Han W; Chen H; Chen Y; Wang F; Liu K; Xu L
Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):89-93. PubMed ID: 24767157
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age.
Deeg HJ; Shulman HM; Anderson JE; Bryant EM; Gooley TA; Slattery JT; Anasetti C; Fefer A; Storb R; Appelbaum FR
Blood; 2000 Feb; 95(4):1188-94. PubMed ID: 10666189
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic bone marrow transplantation for myelodysplastic syndromes (MDS).
Arnold R; Heimpel H
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():101-3. PubMed ID: 2697417
[TBL] [Abstract][Full Text] [Related]
19. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic cell transplantation from alternative donors in children with myelodysplastic syndrome: is that an alternative?
Kalwak K; Wójcik D; Gorczyńska E; Toporski J; Turkiewicz D; Slociak M; Ussowicz M; Pajdosz K; Socha P; Chybicka A
Transplant Proc; 2004 Jun; 36(5):1574-7. PubMed ID: 15251388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
